Topical administration of reversible SAHH inhibitor ameliorates imiquimod‐induced psoriasis‐like skin lesions in mice via suppression of TNF‐&agr;/IFN‐&ggr;‐induced inflammatory response in keratinocytes and T cell‐derived IL‐17